TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04908787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: doxorubicin liposome
Description: Subjects receive doxorubicin liposome, intravenously, d1, , q4w, Dosage form: injectable, Strength: 40mg/m2
Study: NCT06046976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: piesosurgical extraction
Description: exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
Study: NCT04803149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cooled Radiofrequency
Description: Delivery of energy to ablate sensory nerves via cooled radiofrequency probe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Radiofrequency
Description: Delivery of energy to ablate sensory nerves via standard or conventional radiofrequency probe
Study: NCT06046976

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: piesosurgical extraction
Description: exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
Study: NCT05557526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expectation optimization
Description: A short (2-5 min) verbal intervention will be createad individually based on the expectation of the patient towards the procedure.
Study: NCT06046976

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional extraction
Description: exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional extraction
Description: exodontia of multi - rooted teeth in upper/lower jaw using piesosurgical approach
Study: NCT05091528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6050
Description: Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6050
Description: Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6050
Description: Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SBT6050
Description: Dose range of 0.45 to 0.6 mg/kg by subcutaneous (SC) injection in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan
Description: 5.4 mg/kg by intravenous (IV) infusion in 21-day cycles
Study: NCT04828980

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Quest: TRIPP
Description: This is a VR experience that focuses on meditation and mindfulness
Study: NCT05091528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg by mouth (PO) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tucatinib
Description: 300 mg by mouth (PO) twice daily (BID)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles
Study: NCT04828980

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oculus Quest: Angry Birds
Description: This is an active gaming VR experience that utilizes controllers to aim and launch objects at targets.
Study: NCT05091528

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 8 mg/kg loading dose (first dose), then 6 mg/kg maintenance dose (subsequent doses) IV infusion in 21-day cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: 1000 mg/m2 PO BID for 14 days of each 21-day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab deruxtecan
Description: 6.4 mg/kg by IV infusion in 21-day cycles
Study: NCT06379490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.2% Injectable Solution
Description: 30 ml of Ropivacaine 0.2% = 60 mg ropivacaine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine epinephrine
Description: 30 ml of Lidocaine 1% with 5 μg/ml epinephrine = 300 mg lidocaine + 150 μg epinephrine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 0.5% Injectable Solution
Description: 30 mL of Ropivacaine 0.5% = 150 mg Ropivacaine
Study: NCT04698356

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Auditory-cognitive training paradigm
Description: The investigators developed an American English version of the Nottingham (UK) PLUS training paradigm in which listeners are asked to focus and listen to one speaker while ignoring another speaker. The paradigm is designed to optimally enhance the possibility of benefit: an adaptive procedure is employed in order to train each individual at their own level and to make the task challenging. A short-term memory component was also added to the original training paradigm, to enhance the cognitive skills of our participants. To provide maximal speech-in-noise benefit for older, normal-hearing adults, a validation of our new training materials is required. The investigators will evaluate this in young, normal-hearing adults (18-30 years) by studying our outcome measure (speech reception threshold) for the different sentence-scenarios and test-retest sessions.
Study: NCT03766178

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nimotuzumab + SHR-1210
Description: SHR-1210: 200 mg/time, intravenous injection, q2W continuous medication, a course of treatment needs 28 days. The cumulative longest medication period is 2 years.~Nimotuzumab: 200 mg/time, intravenous injection, administered on the 1st and 8th days of each cycle, every 2 weeks is one cycle.
Study: NCT04415541

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychodynamic Psychotherapy
Description: Intensive psychotherapy that is psychodynamically oriented.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Conventional treatment offered in the community.
Study: NCT05148312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Inhalant Product
Description: Single-dose of budesonide solution administered by nebulization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Inhalant Product
Description: Single-dose of budesonide solution administered by nebulization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide Inhalant Product
Description: Single-dose of budesonide solution administered by nebulization.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Budesonide Inhalant Product
Description: Single-dose of budesonide solution administered by nebulization.
Study: NCT05572502

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: plant-based diet
Description: For the duration of the study, this arm will: follow a low-fat vegan diet; weigh themselves weekly, and get fasting bloodwork before, during and after the study
Study: NCT06445998

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: task oriented training
Description: Task-oriented training program: \[For study group\] Rocker board training Wobble board training Sit to stand Walk five steps forward Upstairs and downstairs three steps

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: task oriented training
Description: Task-oriented training program: \[For study group\] Rocker board training Wobble board training Sit to stand Walk five steps forward Upstairs and downstairs three steps
Study: NCT06538688

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Orthodontic extrusion of the impacted mandibular third molar by using the maxillary miniscrew and cross arch elastic power chain as a temporary anchorage device before extraction
Description: Orthodontic extrusion of the impacted mandibular third molar of high-risk for nerve injury using maxillary TAD.
Study: NCT05049148

Intervention type: OTHER
Group type: OTHER
Intervention: Platelet count in excised tumors
Description: Tumors excised in patients requirering a brain or medullary surgery will be assess to determine their platelet count.
Study: NCT05981638

Intervention type: OTHER
Group type: OTHER
Intervention: group WM
Description: Patients were given 5ml/kg dose of water and patients were mobilized.

Intervention type: OTHER
Group type: OTHER
Intervention: group WR
Description: Patients were given 5ml/kg dose of water and patients were rest.

Intervention type: OTHER
Group type: OTHER
Intervention: Group AR
Description: Patients were given 5ml/kg dose of apple juice and patients were rest.

Intervention type: OTHER
Group type: OTHER
Intervention: Group AM
Description: Patients were given 5ml/kg dose of apple juice and patients were mobilized.
Study: NCT06423430

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham-stimulation
Description: Sham-stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active-stimulation
Description: Active DBS
Study: NCT06478498

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus L3 larvae
Description: Necator americanus L3 larvae

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Necator americanus L3 larvae
Description: Necator americanus L3 larvae
Study: NCT04799249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Trilaciclib administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered IV over 30mins prior to chemotherapy on Day 1 and Day 8 of each 21-day cycle.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine administered IV on Day 1 and Day 8 of each 21-day cycle.
Study: NCT06505252

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: enoscopic Myringoplasty
Description: general anesthesia. A single surgeon will perform all surgeries.~* A small incision in the rim of ear lobule on the same side of the operated ear, a small piece of adipose tissue will be removed according to the experience of the surgeon.~* Using 0 angulation endoscope visualization, the edges of the perforation will be refreshed and deepithelialized with a sharp Rosen's needle~* sponge gel (Gelfoam) will pushed through TM perforation into the middle ear to support the graft and to avoid its medialization~* the previously removed fat graft will be inserted through the perforation adjusted so most of the fat piece lying medial to the perforation and small part laterally in patients group A: 0.5 mL of HA vial will be injected directly over the fat graft and the TM remnant. After 5 minutes small gelfoam pieces soaked in 0.5 mL of HA vial will applied over the fat in patients group B PRPG was inserted into the external auditory canal on the outer face of the TM remnant and fat
Study: NCT04799249

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin administered IV on Day 1 and Day 8 of each 21-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin administered IV on Day 1 and Day 8 of each 21-day cycle.
Study: NCT05413408

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Education and contact
Description: The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).~The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education and contact
Description: The intervention consists of three phases, including investigative learning activity (this section will last about one week), higher-order thinking activity (this section will last about two hours), collaborative activity (this section will last about two hours). Both the intervention group and the control group will be interns in the hospital simultaneously. The study outcomes include nursing students' knowledge, attitude, and behavioral intentions regarding stigma towards schizophrenia. The intervention effect will be evaluated by the researcher, comparing results between and within the two groups from baseline (T0) to immediately after first and second session intervention (T1), immediately after third session intervention (T2), and three months follow-up (T3).~The control group only has one session and will be given a book of schizophrenia knowledge, and they will be asked to finish reading it in four weeks.
Study: NCT05899140

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clindamycin
Description: Clindamycin will be administered at a dose of 450 mg TDS (oral) or 10 mg/kg/dose QID iv (maximum 600mg QID iv) for a maximum of 7 days

Intervention type: OTHER
Group type: OTHER
Intervention: Standard of care
Description: Standard of care

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT04557540

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Therapy
Description: Receive The WORD lifestyle CER weight loss intervention

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT05073406

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Altitude exposure in hypobaric normoxic condition
Description: Altitude exposure with oxygen supplementation to achieve normoxia at altitude

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Altitude exposure in hypobaric hypoxic condition
Description: Altitude exposure with air supplementation to obtain a sham comparator arm
Study: NCT04895592

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO or IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Resection
Description: Undergo surgical resection
Study: NCT05850858

Intervention type: DIAGNOSTIC_TEST
Intervention: ascetic fluid study
Description: ascetic fluid study parameter in diagnosis of spontaneous bacterial peritpnitis
Study: NCT05384808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Psychotherapy
Description: Participants receive a standard psychotherapy session with no dog being present.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Canine-assisted psychotherapy with dog actively integrated.
Description: A dog is present and actively integrated into the therapeutic narrative.
Study: NCT04557540

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-Term Fasting
Description: Receive Fasting WORD intermittent fasting weight loss intervention
Study: NCT05863884

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Impact of Community Health Worker Home Deployment on COVID-19 Vaccine Confidence and Uptake
Description: CHWs will conduct home visits to provide diabetes and COVID-19 health education based on the participant's needs, interests, and clinical health assessment results. All adults in the household will be invited to participate in the health education discussions. At each visit, the CHW will use diabetes management and COVID-19 educational materials to facilitate and inform discussions. CHWs will also make available at-home COVID-19 testing kits with instructions for the patient and their household family members. The discussion of COVID-19 beliefs, perceptions, and related behaviors will be raised during a later visit, i.e., after rapport and trust has been established and if it has not been raised by the participants during the earlier visits. In addition, CHWs will help schedule vaccination and healthcare appointments upon participant's interest.
Study: NCT05807490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions BID over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions daily (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions every QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions every 12 hour (BID) or everyday (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days
Study: NCT05384808

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Canine-assisted psychotherapy with dog passively integrated.
Description: A dog is present but not actively integrated into the therapeutic narrative.
Study: NCT05807490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: Single doses of PF-07328948 will be administered as oral suspension (single dose) and oral tablet (single dose) under fed and fasted condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions QD over 14 days
Study: NCT05591937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Self-Guided Online Prevention
Description: An online wellness program that contains self-guided online CBT prevention strategies with demonstrated efficacy for depression and anxiety in college samples. Participants can learn skills for coping with common stressful experiences and build resilience at their own pace.
Study: NCT05807490

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions QD over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07328948
Description: PF-07328948 will be administered as oral suspensions every 12 hour (BID) or daily (QD) over 14 days